Results 41 to 50 of about 1,175 (172)
Uterine fibroid – new possibilities of nosotropic therapy
Гинекология, 2013 In this article are given the results of studies SMRP: ulipristal acetate in the treatment of uterine fibroids, ulipristal acetate (Esmya).
A L Tikhomirov
doaj
Empowering organ-preserving treatment of uterine fibroids using ulipristal acetate [PDF]
Гинекология, 2016 The choice of treatment of uterine leiomyoma affects different factors: the intensity of the symptoms of fibroids characteristics, age and the need for preservation of the uterus (and fertility).
A L Tikhomirov
doaj
The Concise Guide to PHARMACOLOGY 2025/26: Nuclear hormone receptors
British Journal of Pharmacology, Volume 182, Issue S1, Page S242-S258, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +20 more
wiley +1 more source
ULIPRISTAL ACETATE VERSUS PLACEBO FOR FIBROID TREATMENT [PDF]
International Journal of Advanced Research, 2023 Background: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. Methods: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which ...
openaire +2 more sources
Medical treatment of fibroids: FIGO best practice guidance
International Journal of Gynecology &Obstetrics, Volume 171, Issue 2, Page 507-512, November 2025.Abstract Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin‐releasing hormone (GnRH) antagonists have been approved for this
Ivonne Diaz +2 more
wiley +1 more source
Ulipristal acetate as a treatment option for uterine fibroids. [PDF]
Prz Menopauzalny, 2017 Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids.
Piecak K +3 more
europepmc +3 more sources
Capturing Emergency Contraceptive Pill Use: Critical Reflections on Measurement and Reporting
Studies in Family Planning, Volume 56, Issue 3, Page 470-481, September 2025.Abstract Emergency contraceptive pills (ECP) are an essential and unique postcoital method of preventing pregnancy. Trends in supply data show that sales of ECP are increasing at faster rates globally than many other contraceptives. Yet nationally representative survey data suggest that ECP use has remained relatively static overtime, suggesting ...
Joe Strong +3 more
wiley +1 more source
Choosing a Surgical Access Point for Hysterectomy: A Paradigm Shift Over a 10-Year Span
Frontiers in Medicine, 2020 Background: When choosing a surgical procedure for a hysterectomy, doctors and patients have various options in terms of the multiple surgical access points available.
Florian Ebner +8 more
doaj +1 more source
Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 8, Page 1558-1574, August 2025.After 1 year, both uterine artery embolization (UAE) and hysterectomy significantly improved health‐related quality of life (HRQOL) for patients with symptomatic adenomyosis. Neither non‐inferiority nor inferiority could be established within the predefined margins. HRQOL after 1 year was comparable in all HRQOL domains after UAE vs. hysterectomy. Both
Lisa M. Trommelen +40 more
wiley +1 more source